David A. Siegel P Lx Pharma Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.15 - $0.63 $28,080 - $117,936	-187,200 Reduced 92.26%	15,700 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.52 - $3.08 $45,604 - $270,116	-87,700 Reduced 30.18%	202,900 $132,000
Q2 2022 Aug 15, 2022	SELL	$1.9 - $4.18 $195,510 - $430,121	-102,900 Reduced 26.15%	290,600 $706,000
Q1 2022 May 16, 2022	SELL	$3.54 - $8.3 $260,898 - $611,710	-73,700 Reduced 15.77%	393,500 $1.59 Million
Q4 2021 Feb 14, 2022	BUY	$7.69 - $19.66 $609,817 - $1.56 Million	79,300 Added 20.44%	467,200 $3.74 Million

Q3 2021 Nov 15, 2021	BUY	$12.22 - $21.28 $1.48 Million - $2.58 Million	121,300 Added 45.5%	387,900 $7.49 Million
Q2 2021 Aug 16, 2021	BUY	$9.0 - $15.94 $1.7 Million - $3.01 Million	188,900 Added 243.11%	266,600 $3.68 Million
Q1 2021 May 17, 2021	BUY	$5.24 - $10.14 $407,148 - $787,878	77,700 New	77,700 $702,000

61.6K

Ticker PLXP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,137,700
Description
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.